bumetanide + dapagliflozin

**Bumetanide + dapagliflozin** is a **combination of two small molecule diuretics**: bumetanide, a loop diuretic that inhibits the sodium-potassium-chloride symporter (NKCC2) in the thick ascending limb of the loop of Henle, and dapagliflozin, a sodium-glucose cotransporter 2 (SGLT2) inhibitor that blocks glucose and sodium reabsorption in the proximal renal tubule. This combination has been studied experimentally for potential synergistic diuretic effects and management of fluid retention, especially in patients with diabetes mellitus or heart failure. The primary mechanism is the enhanced excretion of sodium and water, but without fully additive effects on first dose; chronic administration demonstrates mutual adaptive natriuretic synergy, and dapagliflozin can reverse bumetanide-induced hyperuricemia. This combination has not been approved as a fixed-dose commercial product and is not available under a proprietary brand name[1][4][5][6].